Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting
Author | Salma, Younes |
Author | Nicolai, Eleonora |
Author | Younes, Nadin |
Author | Pieri, Massimo |
Author | Bernardini, Sergio |
Author | Nizamuddin, Parveen B. |
Author | Al-Sadeq, Duaa W. |
Author | Daas, Hanin I. |
Author | Ismail, Ahmed |
Author | Yassine, Hadi M. |
Author | Abu-Raddad, Laith J. |
Author | Nasrallah, Gheyath K. |
Available date | 2024-09-10T04:22:26Z |
Publication Date | 2024-06-05 |
Publication Name | Vaccine |
Identifier | http://dx.doi.org/10.1016/j.vaccine.2024.06.010 |
ISSN | 0264410X |
Abstract | BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. MethodThe study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. ResultsThe study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). ConclusionThe study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels. |
Sponsor | GKN would like to acknowledge the funding from WHO grant number COVID-19-22-43 and Qatar University grant No. QUCG-BRC-23/24-170. This work was also made possible by grants number UREP29-026-3-004 and UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors. |
Language | en |
Publisher | Elsevier |
Subject | AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologous mRNA vaccination Neutralizing antibody Anti-S1 IgA |
Type | Article |
Open Access user License | http://creativecommons.org/licenses/by/4.0/ |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [727 items ]
-
Biomedical Sciences [711 items ]
-
COVID-19 Research [811 items ]
-
Dental Medicine Research [284 items ]
-
Medicine Research [1418 items ]